A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Change From Baseline in AHV

Change in AHV at week, week 13, week 26, week 39

Time frame: week 4, week 13, week 26, week 39

Change From Baseline in Height Standard Deviation Score (Ht SDS)

Change From Baseline in Ht SDS at week 4, week 13, week 26, week 39, week 52

Time frame: week 4, week 13, week 26, week 39, week 52

Change From Baseline in BMI Standard Deviation Score (BMI SDS)

Change From Baseline in BMI SDS at week 4, week 13, week 26, week 39, week 52

Time frame: week 4, week 13, week 26, week 39, week 52

Change From Baseline in Sitting Height/Leg Length ratio Standard Deviation Score (SH/LL SDS)

Change From Baseline in SH/LL SDS at week 4, week 13, week 26, week 39, week 52

Time frame: week 4, week 13, week 26, week 39, week 52

Change From Baseline in IGF-1 Standard Deviation Score (IGF -1 SDS)

Change From Baseline in IGF-1 SDS at week 4, week 13, week 26, week 39, week 52

Time frame: week 4, week 13, week 26, week 39, week 52

Change From Baseline in IGF-1/IGFBP-3 ratio

Change From Baseline in IGF-1/IGFBP-3 ratio at week 4, week 13, week 26, week 39, week 52

Time frame: week 4, week 13, week 26, week 39, week 52